Anti-GLP-1 antibody [8G9],Abcam,AB26278

What is this antibody validated in? Anti-GLP-1 antibody [8G9] (ab26278) is a mouse monoclonal antibody and is validated for use in Immunohistochemistry (IHC-P), ELISA in Human, Mouse samples. Trusted by the scientific community Anti-GLP-1 [8G9] (ab26278) was first used in a scientific publication in 2005 and has been cited over 20 times in peer-reviewed journals.

Host

Mouse

Reactivity

Mouse, Human

Application

sELISA, IHC-P

Platform ID

BAB131147577

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-GLP-1 antibody [8G9]
Cat. No.AB26278
HostMouse
IsotypeIgG1
ReactivityMouse, Human
ApplicationsELISA, IHC-P
ClonalityMonoclonal
Clone Number8G9
Concentration1.03 mg/mL Batch dependent concentration
ImmunogenSynthetic Peptide within Human GCG aa 50-150. The exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.097% Sodium azide Constituents: PBS, 2.9% Sodium chloride
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Glucagon. Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.. Glucagon-like peptide 1. Potent stimulator of glucose-dependent insulin release. Also stimulates insulin release in response to IL6 (PubMed : 22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis (Probable).. Glucagon-like peptide 2. Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.. Oxyntomodulin. Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.. Glicentin. May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life. See full target information GCG

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.